Medifast, Inc.
Medifast, Inc. MED Peers
See (MED) competitors and their performances in Stock Market.
Peer Comparison Table: Personal Products & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MED | $14.03 | +4.94% | 154.20M | -21.92 | -$0.64 | N/A |
| ROL | $56.95 | +1.03% | 27.60B | 57.53 | $0.99 | +1.14% |
| SCI | $78.46 | +1.96% | 11.17B | 21.67 | $3.62 | +1.55% |
| HRB | $57.68 | +1.67% | 7.72B | 16.20 | $3.56 | +2.51% |
| BFAM | $124.33 | +1.64% | 7.12B | 45.05 | $2.76 | N/A |
| FTDR | $55.30 | +0.45% | 4.07B | 18.01 | $3.07 | N/A |
| DSEY | $8.40 | +0.06% | 2.72B | -14.47 | -$0.58 | N/A |
| MCW | $7.78 | +1.17% | 2.53B | 32.42 | $0.24 | N/A |
| ROVR | $11.00 | +0.05% | 2.00B | 183.25 | $0.06 | N/A |
| CSV | $43.86 | +1.06% | 688.29M | 14.67 | $2.99 | +1.02% |
Stock Comparison
MED vs ROL Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, ROL has a market cap of 27.60B. Regarding current trading prices, MED is priced at $14.03, while ROL trades at $56.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas ROL's P/E ratio is 57.53. In terms of profitability, MED's ROE is -0.03%, compared to ROL's ROE of +0.36%. Regarding short-term risk, MED is more volatile compared to ROL. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs SCI Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, SCI has a market cap of 11.17B. Regarding current trading prices, MED is priced at $14.03, while SCI trades at $78.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas SCI's P/E ratio is 21.67. In terms of profitability, MED's ROE is -0.03%, compared to SCI's ROE of +0.33%. Regarding short-term risk, MED is more volatile compared to SCI. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs HRB Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, HRB has a market cap of 7.72B. Regarding current trading prices, MED is priced at $14.03, while HRB trades at $57.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas HRB's P/E ratio is 16.20. In terms of profitability, MED's ROE is -0.03%, compared to HRB's ROE of -1.68%. Regarding short-term risk, MED is more volatile compared to HRB. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs BFAM Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, BFAM has a market cap of 7.12B. Regarding current trading prices, MED is priced at $14.03, while BFAM trades at $124.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas BFAM's P/E ratio is 45.05. In terms of profitability, MED's ROE is -0.03%, compared to BFAM's ROE of +0.12%. Regarding short-term risk, MED is more volatile compared to BFAM. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs FTDR Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, FTDR has a market cap of 4.07B. Regarding current trading prices, MED is priced at $14.03, while FTDR trades at $55.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas FTDR's P/E ratio is 18.01. In terms of profitability, MED's ROE is -0.03%, compared to FTDR's ROE of +1.04%. Regarding short-term risk, MED is more volatile compared to FTDR. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs DSEY Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, DSEY has a market cap of 2.72B. Regarding current trading prices, MED is priced at $14.03, while DSEY trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas DSEY's P/E ratio is -14.47. In terms of profitability, MED's ROE is -0.03%, compared to DSEY's ROE of -0.23%. Regarding short-term risk, MED is more volatile compared to DSEY. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs MCW Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, MCW has a market cap of 2.53B. Regarding current trading prices, MED is priced at $14.03, while MCW trades at $7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas MCW's P/E ratio is 32.42. In terms of profitability, MED's ROE is -0.03%, compared to MCW's ROE of +0.08%. Regarding short-term risk, MED is more volatile compared to MCW. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs ROVR Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, ROVR has a market cap of 2.00B. Regarding current trading prices, MED is priced at $14.03, while ROVR trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas ROVR's P/E ratio is 183.25. In terms of profitability, MED's ROE is -0.03%, compared to ROVR's ROE of +0.04%. Regarding short-term risk, MED is more volatile compared to ROVR. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs CSV Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, CSV has a market cap of 688.29M. Regarding current trading prices, MED is priced at $14.03, while CSV trades at $43.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas CSV's P/E ratio is 14.67. In terms of profitability, MED's ROE is -0.03%, compared to CSV's ROE of +0.23%. Regarding short-term risk, MED is more volatile compared to CSV. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs EM Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, EM has a market cap of 120.19M. Regarding current trading prices, MED is priced at $14.03, while EM trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas EM's P/E ratio is -111.00. In terms of profitability, MED's ROE is -0.03%, compared to EM's ROE of -0.01%. Regarding short-term risk, MED is more volatile compared to EM. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs YYGH Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, YYGH has a market cap of 61.20M. Regarding current trading prices, MED is priced at $14.03, while YYGH trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas YYGH's P/E ratio is -11.43. In terms of profitability, MED's ROE is -0.03%, compared to YYGH's ROE of -0.78%. Regarding short-term risk, MED is less volatile compared to YYGH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs XSPA Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, XSPA has a market cap of 54.52M. Regarding current trading prices, MED is priced at $14.03, while XSPA trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas XSPA's P/E ratio is 21.83. In terms of profitability, MED's ROE is -0.03%, compared to XSPA's ROE of -1.20%. Regarding short-term risk, MED is less volatile compared to XSPA. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs RGS Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, RGS has a market cap of 50.47M. Regarding current trading prices, MED is priced at $14.03, while RGS trades at $20.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas RGS's P/E ratio is 0.56. In terms of profitability, MED's ROE is -0.03%, compared to RGS's ROE of +1.58%. Regarding short-term risk, MED is less volatile compared to RGS. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs WW Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, WW has a market cap of 20.04M. Regarding current trading prices, MED is priced at $14.03, while WW trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas WW's P/E ratio is -0.29. In terms of profitability, MED's ROE is -0.03%, compared to WW's ROE of +0.06%. Regarding short-term risk, MED is less volatile compared to WW. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs EJH Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, EJH has a market cap of 19.69M. Regarding current trading prices, MED is priced at $14.03, while EJH trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas EJH's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.03%, compared to EJH's ROE of -0.15%. Regarding short-term risk, MED is less volatile compared to EJH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs TRNR Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, TRNR has a market cap of 8.47M. Regarding current trading prices, MED is priced at $14.03, while TRNR trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas TRNR's P/E ratio is -0.01. In terms of profitability, MED's ROE is -0.03%, compared to TRNR's ROE of -13.46%. Regarding short-term risk, MED is less volatile compared to TRNR. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs MRM Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, MRM has a market cap of 6.64M. Regarding current trading prices, MED is priced at $14.03, while MRM trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas MRM's P/E ratio is 4.43. In terms of profitability, MED's ROE is -0.03%, compared to MRM's ROE of -0.39%. Regarding short-term risk, MED is less volatile compared to MRM. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs XWEL Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, XWEL has a market cap of 4.79M. Regarding current trading prices, MED is priced at $14.03, while XWEL trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas XWEL's P/E ratio is -0.25. In terms of profitability, MED's ROE is -0.03%, compared to XWEL's ROE of -2.71%. Regarding short-term risk, MED is less volatile compared to XWEL. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs IVP Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 154.20M. In comparison, IVP has a market cap of 3.69M. Regarding current trading prices, MED is priced at $14.03, while IVP trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.92, whereas IVP's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.03%, compared to IVP's ROE of -11.83%. Regarding short-term risk, MED is less volatile compared to IVP. This indicates potentially lower risk in terms of short-term price fluctuations for MED.